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Challenges and Benefits in Using Productivity Data from
Clinical Trials for VBP Decisions
Thomas J. Bunz, PharmD and
Laura T. Pizzi, PharmD, MPH
Making value based purchasing decisions in healthcare requires balancing data
from several sources. Information on effectiveness of interventions often comes
from clinical trials, with less reliance on observational studies. Historically, the
opposite has been true of information on the cost of interventions. More recently,
providers of healthcare interventions such as drugs, devices, and disease
management programs have begun to understand and appreciate the
importance of costs in healthcare decision making. Because of this, the clinical
trials used to demonstrate effectiveness have begun to gather data on costs.
This article describes some benefits and detriments of collecting cost data as a
component of clinical trials, focusing specifically on the data related to
productivity.
Studies evaluating the cost of an intervention can look at a variety of different
types of costs depending on the perspective of the study. For an organization
whose sole function is to pay for healthcare (e.g., Pharmacy Benefits Managers),
the direct costs (e.g., the price of a pharmaceutical) are the only ones with
importance. For employers, it is essential to consider the indirect costs and, in
particular, productivity.
Productivity can be measured in a variety of ways, but it is usually reported as an
amount of productivity lost due to a certain disease, or the amount of productivity
loss avoided by using a specific type of intervention. Productivity loss due to
medical conditions can present itself in 2 ways. The first is absenteeism, often
measured by means of reviewing employee records of sick days or disability
leave.
The second type of productivity loss - presenteeism - is more difficult to measure.
Presenteeism is defined as an employee being present at the work place but
unable to perform at his or her usual level of productivity. This type of
productivity loss is often measured by surveying employees with certain
conditions. The employees are asked to report the percent of time they have lost
from work as a result of their condition.
The value of lost productivity can be calculated through either the friction cost
approach, or the human capital approach. The human capital approach yields
estimates of wages lost for the time that an employee was not working. The
friction cost approach adds to that the cost of recruiting and training additional
labor to replace that which was lost. Depending on the condition and the
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characteristics of the work environment, either of these approaches may be
appropriate.
Using clinical trials to measure changes in productivity due to a medical
intervention has a number of benefits. These trials are viewed as the gold
standard for understanding the impact of medical interventions on health
because they control for a lot of potentially confounding issues. In these trials,
patients are carefully controlled on one or more specific interventions, and the
outcomes are measured prospectively. This allows researchers to arrive at
strong conclusions about the causes and effects observed in the trial.
There are also some limitations when using clinical trials to measures
productivity changes due to medical interventions. First, one must recognize that
health is only one of many factors that contribute to work productivity. Changes
observed during a clinical trial may not be due entirely to the intervention being
tested. In addition, some individuals choose their jobs, at least in part, in order to
mitigate the limitations of that condition. For example, a retail worker with back
pain may choose to look for a job at a pharmacy rather than a home
improvement store in order to lessen the likelihood of heavy lifting as a job
requirement. This type of decision lessens the perceived impact of a medical
intervention on productivity from a clinical trial point of view.
Interpreting studies that evaluate the impact of medical interventions on
productivity can be difficult, but it is an essential step in understanding the effect
of purchasing decisions on employees. For instance, it is important to
understand how the conditions in which the study was conducted differ from
those at the company purchasing the medical intervention. The type of work
being done as well as the demographic characteristics of the workers may
influence the estimation of wages for those workers.
Although it has been demonstrated that productivity loss is one of the largest
disease-associated costs for employers, we are still in the early stages of
measuring productivity gains due to specific interventions. As this important
information becomes more available, employers should recognize its value in
making purchasing decisions. It is equally important that the consumers of this
information understand the benefits and detriments of these study designs.
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